Healthcare Sales & Marketing Network News: human monoclonal antibody

Searching News Database: human monoclonal antibody

HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Biopharmaceuticals Drug Delivery FDA

HSMN NewsFeed - 21 Sep 2022
Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 11 Jul 2022
Anthos Therapeutics Announces that Abelacimab has Received FDA Fast Track Designation for the Treatment of Thrombosis Associated with Cancer
Biopharmaceuticals FDA

HSMN NewsFeed - 9 Dec 2021
Richter and Hikma sign exclusive commercialisation and license agreement for denosumab in the US, a proposed biosimilar referencing Prolia(R) and Xgeva(R)
Biopharmaceuticals Generics Licensing

HSMN NewsFeed - 20 Oct 2021
FDA Expands Approval of Dupixent(R) (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Biopharmaceuticals FDA

HSMN NewsFeed - 1 Jun 2021
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Dec 2020
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Biopharmaceuticals

HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Nov 2020
Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma
Biopharmaceuticals

HSMN NewsFeed - 12 Aug 2020
FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 14 Jul 2020
TREMFYA(R) (guselkumab) Approved by U.S. Food and Drug Administration as the First Selective Interleukin (IL)-23 Inhibitor for Active Psoriatic Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Jun 2020
Dupixent(R) (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 8 Jun 2020
Amplyx Pharmaceuticals Expands Executive Leadership Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Nov 2019
Regeneron Provides Updates on Phase 3 Libtayo(R) (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Oct 2019
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Biopharmaceuticals Cardiology Reimbursement

HSMN NewsFeed - 6 Aug 2019
Dupixent(R) (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 14 Jun 2019
Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Biopharmaceuticals

HSMN NewsFeed - 7 May 2019
Dupixent(R) (dupilumab) Approved for Severe Asthma by European Commission
Biopharmaceuticals Regulatory

HSMN NewsFeed - 1 Mar 2019
CHMP Recommends Approval of Dupixent(R) (dupilumab) for Asthma Indication
Biopharmaceuticals Regulatory

HSMN NewsFeed - 30 Jan 2019
CardioVax Announces Name Change to Abcentra
Biopharmaceuticals

HSMN NewsFeed - 28 Nov 2018
MabVax Therapeutics Holdings, Inc. Announces $1.0 Million Equity Purchase Agreement
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 30 Apr 2018
FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Apr 2018
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia(R) (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 Mar 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 2 Mar 2018
FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Feb 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Jan 2018
Regeneron Announces Approval of DUPIXENT(R) (dupilumab) in Japan for the Treatment of Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 5 Jan 2018
FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Nov 2017
Neurimmune Announces Collaboration With Ono Pharmaceutical in Neurodegenerative Diseases Field
Biopharmaceuticals Neurology

HSMN NewsFeed - 12 Oct 2017
Ortho Dermatologics Announces Two-Year Findings From Pivotal Phase 3 Study Of SILIQ(TM) (brodalumab) Injection Data Demonstrating Long-Term Efficacy Profile
Biopharmaceuticals Dermatology

HSMN NewsFeed - 28 Sep 2017
Regeneron and Sanofi Announce Approval of DUPIXENT(R) (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 25 Aug 2017
Regeneron and Sanofi to Present New Analyses from Praluent(R) (alirocumab) Injection Trials at the ESC Congress 2017
Biopharmaceuticals Cardiology

HSMN NewsFeed - 28 Jul 2017
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha(R) (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 27 Jul 2017
Valeant Announces U.S. Launch of SILIQ(TM) (brodalumab) Injection
Biopharmaceuticals Dermatology Product Launch

HSMN NewsFeed - 19 Jun 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology

HSMN NewsFeed - 18 May 2017
Amgen Submits Biologics License Application To The FDA For Erenumab
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 28 Apr 2017
Regeneron and Sanofi Announce Kevzara(R) (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 24 Apr 2017
Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara(R) (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 21 Apr 2017
Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ(TM) (Brodalumab) As The Lowest Priced Injectable Biologic For Moderate-To-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 17 Apr 2017
OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 Mar 2017
Sanofi and Regeneron Announce FDA Approval of Dupixent(R) (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 20 Mar 2017
Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
Biopharmaceuticals Cardiology

HSMN NewsFeed - 28 Feb 2017
Kevzara(TM) (sarilumab) now available in Canada for the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis
Biopharmaceuticals Product Launch

HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 16 Feb 2017
Valeant Receives FDA Approval Of SILIQ(TM) (Brodalumab) For Moderate-To-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 3 Feb 2017
Amgen Announces Repatha(R) (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Biopharmaceuticals Cardiology

HSMN NewsFeed - 16 Dec 2016
Janssen Submits Application Seeking FDA Approval of STELARA(R) (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 30 Nov 2016
Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 24 Nov 2016
Kymab Secures US$100 Million Series C Funding
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 17 Nov 2016
Regeneron and Sanofi Announce Praluent(R) (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis
Biopharmaceuticals

HSMN NewsFeed - 29 Aug 2016
New Repatha(R) (evolocumab) Analyses Show Efficacy and Safety Across Risk Groups in Results Presented at ESC Congress 2016
Biopharmaceuticals Cardiology

HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 5 Jul 2016
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 5 Jul 2016
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 1 Jul 2016
Valeant Pharmaceuticals Announces New Licensing Arrangement For Brodalumab In Europe
Biopharmaceuticals Licensing

HSMN NewsFeed - 27 Apr 2016
Novartis Receives Three FDA Breakthrough Therapy Designations for IlaristTo Treat Rare Types of Periodic Fever Syndromes
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Mar 2016
Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 2 Mar 2016
Merck KGaA, Darmstadt, Germany Initiates Phase III Study of MSB11022, a Proposed Biosimilar of Adalimumab, in Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 22 Feb 2016
Amgen And UCB Announce Positive Top-Line Results From The Phase 3 Study Of Romosozumab In Postmenopausal Women With Osteoporosis
Biopharmaceuticals

HSMN NewsFeed - 4 Feb 2016
Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha(R) (Evolocumab) In Statin-Intolerant Patients With High Cholesterol
Biopharmaceuticals

HSMN NewsFeed - 25 Jan 2016
Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 22 Jan 2016
Amgen's Repatha(R) (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Biopharmaceuticals Regulatory

HSMN NewsFeed - 19 Jan 2016
Acorda to Acquire Biotie Therapies
Biopharmaceuticals Neurology Mergers & Acquisitions

HSMN NewsFeed - 16 Jan 2016
Novartis receives two new FDA approvals for Cosentyx(R) (secukinumab) to treat patients with ankylosing spondylitis and psoriatic arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 4 Nov 2015
Vaccinogen Promotes Peter Morsing, Ph.D. to Chief Operating Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Nov 2015
Shire to Acquire Dyax Corp, Expanding and Extending Industry-Leading Hereditary Angioedema (HAE) Portfolio
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 16 Sep 2015
Amgen To Acquire Privately-Held Dezima Pharma
Biopharmaceuticals Cardiology Mergers & Acquisitions

HSMN NewsFeed - 11 Sep 2015
Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha(TM) (Evolocumab)
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 1 Sep 2015
Valeant And AstraZeneca To Partner On Brodalumab
Biopharmaceuticals Dermatology Licensing Distribution

HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia
Biopharmaceuticals Regulatory

HSMN NewsFeed - 14 Jul 2015
Aridis Pharmaceuticals Appoints Fred Kurland as Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 21 May 2015
Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 27 Mar 2015
Trillium Announces Appointment of Eric L. Sievers, M.D. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 16 Apr 2014
Dyax Corp. Announces Appointment of Todd Bazemore as Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Mar 2014
Stem Cell Therapeutics Strengthens its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 30 Jan 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 13 Jan 2014
Agenus Appoints Robert B. Stein, MD, PhD, as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Dec 2013
Celldex Therapeutics Initiates METRIC, an Accelerated Approval Study of Glembatumumab Vedotin in Patients with Triple Negative Breast Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Nov 2013
Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial
Biopharmaceuticals

HSMN NewsFeed - 7 Nov 2013
ImmunGene Raises $9 Million in Series A Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 31 Oct 2013
Stem Cell Therapeutics Receives U.S. Orphan Drug Designation for the Use of Tigecycline to Treat Acute Myeloid Leukemia
Regenerative Medicine Oncology FDA

HSMN NewsFeed - 4 Oct 2013
GSK and Genmab Announce European Submission to Regulatory Authorities for Arzerra(R) (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 15 May 2013
Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
Biopharmaceuticals

HSMN NewsFeed - 25 Mar 2013
Arzerra Receives Approval in Japan
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 8 Nov 2012
Immune Pharmaceuticals and EpiCept Corporation Agree to Merge
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 20 Aug 2012
Dyax Corp. Creates COO Position and Expands Executive Roles
Biopharmaceuticals Personnel

HSMN NewsFeed - 10 Aug 2012
PharmAthene Receives FDA Notification On SparVax(TM)
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Jul 2012
Human Genome Sciences Announces Resubmission of Raxibacumab BLA to FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Mar 2012
Genmab Provides Update on Ofatumumab Phase III Head to Head Study in DLBCL
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Nov 2011
PharmAthene Appoints Linda L. Chang Senior Vice President, Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 13 Sep 2011
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 30 Aug 2011
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR(R) in Patients with Non-Cancer Pain
Biopharmaceuticals FDA

HSMN NewsFeed - 15 Jul 2011
XGEVA(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory

HSMN NewsFeed - 19 May 2011
Lilly Presents Data on Cixutumumab in Five Subtypes of Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 7 Jan 2011
MedImmune In-Licenses Clinical-Stage Anti-Inflammatory Monoclonal Antibody From Amgen
Biopharmaceuticals Licensing

HSMN NewsFeed - 13 Dec 2010
XGEVA (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 8 Nov 2010
New Magnetic Resonance Imaging (MRI) Data Show Efficacy of SIMPONI(R) in Treatment of Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 6 Oct 2010
New Data Demonstrate Treatment With STELARA(R) (Black Triangle Drug) (ustekinumab) Results in Sustained Improvements in Psoriasis Severity and Quality of Life up to Three Years
Biopharmaceuticals Dermatology

HSMN NewsFeed - 27 Sep 2010
Centocor Ortho Biotech Inc. Submits Application to FDA Seeking to Expand SIMPONI(R) Label in Treatment of Rheumatoid Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 10 Jun 2010
Human Genome Sciences Announces Submission of Biologics License Application to FDA for BENLYSTA(R) (belimumab)
Biopharmaceuticals

HSMN NewsFeed - 7 Jun 2010
Human Genome Sciences Announces Submission of Marketing Authorization Application to EMA for BENLYSTA(R) (Belimumab)
Biopharmaceuticals

HSMN NewsFeed - 19 May 2010
STELARA(TM) Significantly Improves Symptoms of Depression, Anxiety and Health-Related Quality of Life in Patients With Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 3 May 2010
PharmAthene Appoints Eric I. Richman as Interim Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Apr 2010
Human Genome Sciences and GlaxoSmithKline Announce Topline 76-Week Results of Phase 3 Trial of BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 30 Mar 2010
PharmAthene Appoints Eric I. Richman as President and Chief Operating Officer and Announces Senior Management Promotions
Biopharmaceuticals Personnel

HSMN NewsFeed - 8 Feb 2010
Denosumab Demonstrated Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Prostate Cancer Patients With Bone Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Jan 2010
Arzerra(TM) (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europe for Refractory Chronic Lymphocytic Leukaemia
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 14 Jan 2010
STELARA(TM) (ustekinumab) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 10 Dec 2009
Data Presented at San Antonio Breast Cancer Symposium Demonstrate Treatment with Denosumab is Superior to the Standard of Care
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 Nov 2009
Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 27 Oct 2009
Sorrento Therapeutics Announces the Appointment of Martina Molsbergen as Vice President, Business Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Oct 2009
Human Genome Sciences and GlaxoSmithKline Announce Full Presentation at ACR of Positive Phase 3 Study Results for BENLYSTA in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Long-Term Efficacy in Treatment of Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals

HSMN NewsFeed - 19 Oct 2009
Amgen Provides Update on Status of Prolia(TM) (Denosumab) Biologics License Application (BLA) Submitted to the U.S. Food and Drug Administration (FDA)
Biopharmaceuticals FDA

HSMN NewsFeed - 6 Oct 2009
SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
Biopharmaceuticals Regulatory

HSMN NewsFeed - 23 Sep 2009
Janssen-Cilag's STELARA(R) (Black Triangle Drug) (ustekinumab) Approved by NICE for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory

HSMN NewsFeed - 22 Sep 2009
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Sep 2009
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 26 Aug 2009
Genmab Announces Positive Top-Line Results for Arzerra(TM) in Front Line NHL
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Aug 2009
New Delivery System for RELISTOR in Pre-Filled Syringes Submitted for U.S. and European Marketing Approval
Biopharmaceuticals

HSMN NewsFeed - 27 Jul 2009
Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Biopharmaceuticals

HSMN NewsFeed - 20 Jul 2009
Human Genome Sciences and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 26 Jun 2009
SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 24 Apr 2009
SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals FDA

HSMN NewsFeed - 21 Apr 2009
Merck & Co., Inc., Medarex, Inc. and Massachusetts Biologic Laboratories Sign Exclusive Licensing Agreement for Investigational Monoclonal Antibody Combination for Clostridium Difficile Infection
Biopharmaceuticals Licensing

HSMN NewsFeed - 23 Feb 2009
Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 5 Feb 2009
GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra (Ofatumumab) in Advanced Stage Blood Cancer
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 22 Jan 2009
New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 19 Dec 2008
Amgen Submits Biologics License Application for FDA Approval of Denosumab in Women With Postmenopausal Osteoporosis and in Patients Undergoing Hormone Ablation for Either Prostate or Breast Cancer
Biopharmaceuticals

HSMN NewsFeed - 21 Oct 2008
Abbott's HUMIRA(R) (adalimumab) Data Shows Fistula Healing for Up to Three Years in Patients with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 26 Sep 2008
4-Antibody Appoints Dr. Richard Mason as New Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 18 Sep 2008
Findings From Landmark Study Show Ustekinumab Demonstrated Superior Efficacy to Enbrel(R) (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 18 Sep 2008
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Biopharmaceuticals Dermatology

HSMN NewsFeed - 15 Sep 2008
Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate
Biopharmaceuticals

HSMN NewsFeed - 8 Aug 2008
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
Biopharmaceuticals FDA

HSMN NewsFeed - 31 Jul 2008
Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Biopharmaceuticals Oncology

HSMN NewsFeed - 25 Jul 2008
Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial
Biopharmaceuticals

HSMN NewsFeed - 14 Jul 2008
Amgen Announces Positive Top-Line Results for Denosumab Treatment of Bone Loss in Men With Non-Metastatic Prostate Cancer Undergoing Androgen Deprivation Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 3 Jul 2008
Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients
Biopharmaceuticals Regulatory

HSMN NewsFeed - 17 Jun 2008
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 13 Jun 2008
Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
Biopharmaceuticals

HSMN NewsFeed - 13 Jun 2008
HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
Biopharmaceuticals

HSMN NewsFeed - 13 Jun 2008
New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 31 May 2008
Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2008
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
Biopharmaceuticals Oncology

HSMN NewsFeed - 28 May 2008
New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
Biopharmaceuticals

HSMN NewsFeed - 28 May 2008
Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial versus Weekly Alendronate (FOSAMAX(R))
Biopharmaceuticals

HSMN NewsFeed - 19 May 2008
Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study
Biopharmaceuticals

HSMN NewsFeed - 24 Apr 2008
Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
Biopharmaceuticals Regulatory

HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 2 Apr 2008
Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women
Biopharmaceuticals

HSMN NewsFeed - 1 Apr 2008
Wyeth and Progenics Announce RELISTOR Receives Canadian Marketing Approval
Biopharmaceuticals Regulatory

HSMN NewsFeed - 25 Mar 2008
Micromet Establishes New Scientific Advisory Board for Its BiTE Antibody Technology with Leading Experts in the Fields of Oncology, Immunotherapy and Drug Development
Biopharmaceuticals Personnel

HSMN NewsFeed - 12 Mar 2008
Wyeth and Progenics Provide Update on Phase 3 Clinical Trial of Intravenous Methylnaltrexone for Postoperative Ileus
Biopharmaceuticals

HSMN NewsFeed - 21 Feb 2008
ImmunoCellular Therapeutics Announces New President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Feb 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 24 Jan 2008
Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))
Biopharmaceuticals

HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 14 Dec 2007
Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Dec 2007
Micromet Announces Changes in Management Team
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Dec 2007
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 16 Nov 2007
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory

HSMN NewsFeed - 9 Nov 2007
Human Genome Sciences Reports Positive Data from Long-Term Treatment with LymphoStat-B(R) in Patients with Active Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 29 Oct 2007
AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
Biopharmaceuticals

HSMN NewsFeed - 22 Oct 2007
AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. Announce Merger Agreement
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 8 Oct 2007
AVANIR Granted Special Protocol Assessment (SPA) From FDA for Confirmatory Phase III Trial of Zenvia in Patients With PBA
Biopharmaceuticals Neurology

HSMN NewsFeed - 3 Oct 2007
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Biopharmaceuticals Dermatology

HSMN NewsFeed - 12 Sep 2007
Micromet Appoints Mark Reisenauer as Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 29 Aug 2007
Wyeth and Progenics Submit Marketing Application in Australia for Subcutaneous Methylnaltrexone
Biopharmaceuticals Regulatory

HSMN NewsFeed - 6 Aug 2007
AVANIR Pharmaceuticals Completes Sale Of FazaClo
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 19 Jul 2007
Micromet Promotes Carsten Reinhardt to Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Jul 2007
AVANIR Pharmaceuticals Announces Sale of FazaClo to Fund Continued Development of Zenvia
Biopharmaceuticals

HSMN NewsFeed - 15 Jun 2007
Three Studies Suggest Abbott's HUMIRA(R) (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Biopharmaceuticals

HSMN NewsFeed - 14 Jun 2007
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B(R) Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 4 Jun 2007
Final Data from a Phase 2 Trial Presented at ASCO Specifies Dose-dependent Activity of Adecatumumab (MT201)
Biopharmaceuticals Oncology

HSMN NewsFeed - 31 May 2007
Progenics and Wyeth Announce FDA Has Accepted For Filing the New Drug Application for Subcutaneous Methylnaltrexone
Biopharmaceuticals Regulatory

HSMN NewsFeed - 30 May 2007
Human Genome Sciences and GlaxoSmithKline Initiate Second Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 22 May 2007
New Analysis of Data Shows Treatment With Abbott's HUMIRA(R) (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 7 May 2007
Abbott Seeks U.S. and E.U. Regulatory Approvals for HUMIRA(R) (Adalimumab) as a Treatment for Juvenile Rheumatoid Arthritis
Biopharmaceuticals FDA Regulatory

HSMN NewsFeed - 4 May 2007
Abbott's Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
Biopharmaceuticals Dermatology

HSMN NewsFeed - 1 May 2007
Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
Biopharmaceuticals HIV/AIDS

HSMN NewsFeed - 16 Apr 2007
Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
Biopharmaceuticals Oncology

HSMN NewsFeed - 10 Apr 2007
Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico
Biopharmaceuticals

HSMN NewsFeed - 2 Apr 2007
Abbott Seeks U.S. and E.U. Regulatory Approval for HUMIRA(R) (Adalimumab) in Psoriasis
Biopharmaceuticals Dermatology FDA

HSMN NewsFeed - 30 Mar 2007
Progenics and Wyeth Announce Submission of New Drug Application for the Subcutaneous Formulation of Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients Receiving Palliative Care
Biopharmaceuticals Drug Delivery

HSMN NewsFeed - 22 Mar 2007
Eisai To Acquire Morphotek
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 16 Mar 2007
Micromet and TRACON Pharmaceuticals Sign Exclusive Worldwide License Agreement to Develop and Commercialize D93, a Humanized Antibody for Cancer Treatment
Biopharmaceuticals Licensing

HSMN NewsFeed - 27 Feb 2007
HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 13 Feb 2007
Human Genome Sciences and GlaxoSmithKline Announce Initiation of Phase 3 Clinical Trial of LymphoStat-B(R) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 12 Feb 2007
Morphotek Obtains Exclusive License from Micromet for Antibody to Treat Melanoma and Other Cancers
Biopharmaceuticals Licensing

HSMN NewsFeed - 2 Feb 2007
Psoriasis Patients Show Significant Improvement in Symptoms with Abbott's HUMIRA(R) in New Phase III Study
Biopharmaceuticals Dermatology

HSMN NewsFeed - 8 Jan 2007
Cambridge Antibody Technology Licenses Monoclonal Antibody (CAT-213) for Treatment of Allergy Disorders to iCo Therapeutics
Biopharmaceuticals Licensing

HSMN NewsFeed - 8 Jan 2007
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2007 Goals at JPMorgan Healthcare Conference
Biopharmaceuticals

HSMN NewsFeed - 8 Jan 2007
Progenics Pharmaceuticals Expands Senior Management Team and Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 20 Dec 2006
Regeneron Reports Blocking New Angiogenesis Target May Offer Novel Approach to Slowing Tumor Growth
Biopharmaceuticals Oncology

HSMN NewsFeed - 20 Dec 2006
Wyeth and Progenics Initiate Second Global Phase 3 Trial of Intravenous Methylnaltrexone to Treat Post-operative Ileus
Biopharmaceuticals

HSMN NewsFeed - 19 Dec 2006
GlaxoSmithKline and Genmab Enter Global Agreement For HuMax-CD20
Biopharmaceuticals Oncology

HSMN NewsFeed - 5 Dec 2006
Micromet, Inc. and Serono Amend Collaboration Agreement and Continue Development of Adecatumumab (MT201)
Biopharmaceuticals Oncology

HSMN NewsFeed - 14 Nov 2006
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval for Inhibiting Structural Joint Damage and Improving Physical Function in Patients With Psoriatic Arthritis
Biopharmaceuticals FDA

HSMN NewsFeed - 14 Nov 2006
Human Genome Sciences Announces Positive 76-Week Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 26 Oct 2006
Abbott's HUMIRA(R) (Adalimumab) Granted FDA Priority Review for the Treatment of Moderately to Severely Active Crohn's Disease
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 26 Oct 2006
Human Genome Sciences Announces Positive Special Protocol Assessment From FDA for Phase 3 Clinical Trials of LymphoStat-B(TM) In Systemic Lupus Erythematosus
Biopharmaceuticals FDA

HSMN NewsFeed - 23 Oct 2006
New Phase III Data Shows Abbott's HUMIRA(R) (Adalimumab) Induced Clinical Remission In Patients With Crohn's Disease Who Lost Response to, or Were Intolerant to, Remicade(R) (Infliximab)
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 12 Oct 2006
Micromet, Inc. Expands Management and Appoints Christopher P. Schnittker as Senior Vice President and Chief Financial Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Oct 2006
Human Genome Sciences Reports Significant Progress and Outlines Its Next Steps on the Path to Commercialization
Biopharmaceuticals

HSMN NewsFeed - 2 Oct 2006
Final Data From Two Phase II Trials Indicate Activity of Adecatumumab (MT201) in Breast and Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Sep 2006
FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 20 Sep 2006
Progenics and Wyeth Initiate Global Phase 3 Clinical Program of Intravenous Methylnaltrexone to Treat Post-Operative Ileus
Biopharmaceuticals

HSMN NewsFeed - 7 Sep 2006
Abbott Submits U.S. and E.U. Regulatory Applications Seeking Approval for HUMIRA(R) (Adalimumab) as a Treatment for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA

HSMN NewsFeed - 17 Jul 2006
Wyeth and Progenics Announce Methylnaltrexone Receives FDA Fast Track Designation for Treatment of Postoperative Ileus
Biopharmaceuticals FDA

HSMN NewsFeed - 26 Jun 2006
Abbott Receives FDA Approval for New HUMIRA(R) Delivery Device
Biopharmaceuticals FDA Drug Delivery

HSMN NewsFeed - 22 Jun 2006
Human Genome Sciences Announces Full Presentation of Results of Phase 2 Clinical Trial of LymphoStat-B(TM) in Systemic Lupus Erythematosus
Biopharmaceuticals

HSMN NewsFeed - 22 May 2006
Promising Pivotal Phase III Data Show Abbott's Humira(R) (Adalimumab) Maintained Clinical Remission in Patients With Crohn's Disease Through One Year
Biopharmaceuticals Gastroenterology

HSMN NewsFeed - 5 May 2006
Micromet and CancerVax Complete Merger To Form Micromet, Inc.
Biopharmaceuticals Mergers & Acquisitions

Return to NewsFeed

Additional items found! 120

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 120 additional stories matching:
human monoclonal antibody
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.